세계의 네오스티그민메틸황산염 주사제 시장 : 용량별, 적응증별, 유통 경로별, 최종 용도별, 지역별
Neostigmine Methylsulfate Injection Market, By Dosage, By Indication, By Distribution Channel, By End Use, By Geography
상품코드
:
1741283
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
네오스티그민메틸황산염 주사제 시장은 2025년에는 1억 7,150만 달러로 평가되었고, 2032년에는 2억 3,340만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지의 연평균 성장률(CAGR)은 4.5%를 보일 것으로 전망됩니다.
| 보고 범위 |
보고서 세부 정보 |
| 기준 연도 |
2024년 |
2025년 시장 규모 |
1억 7,150만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| CAGR(2025-2032년) |
4.50% |
가치 예측(2032년) |
2억 3,340만 달러 |
네오스티그민메틸황산염 주사제는 중증 근육 무력증의 치료 보조제로 사용되며, 수술실이나 중환자실 환경에서 비탈분극성 신경근 차단제 중독의 해독제로 사용되는 콜린에스테라제 억제제입니다. 이 약물은 신경근 접합부에서 신경전달물질인 아세틸콜린을 분해하는 아세틸콜린에스테라제 효소를 억제함으로써 작용합니다. 이 효소를 억제함으로써 네오스티그민메틸황산염는 아세틸콜린의 작용 시간을 연장시켜 신경근 전달을 증가시키고 근육 강도를 향상시킵니다. 근육 무력증 증상인 사지, 몸통, 목, 눈의 골격근 약화를 관리하는 데 도움을 줍니다. 과량 투여나 민감한 환자에게는 신경근 접합부에서의 과도한 자극을 유발하여 메스꺼움, 타액 증가, 근육 경련 등의 부작용을 일으킬 수 있습니다.
시장 역학 :
노인 인구의 증가로 인해 예측 기간 동안 전 세계 네오스티그민메틸황산염 주사제 시장이 지속적으로 성장할 것으로 예상됩니다. 노인들은 중증 근육 무력증과 같은 신경계 질환에 더 취약하며, 이는 종종 네오스티그민메틸황산염 주사로 치료가 필요합니다. 의료 비용의 증가도 예측 기간 동안 전 세계 네오스티그민메틸황산염 주사제 시장 성장을 촉진할 것입니다. 수의학 분야의 성장은 예측 기간 동안 세계의 네오스티그민메틸황산염 주사제 시장에게 새로운 기회를 창출할 것입니다. 네오스티그민메틸황산염 주사제는 수의학 분야에서도 사용되며, 특히 동물에서 일부 신경근육 질환의 치료에 활용됩니다. 이는 수의학 산업에서 네오스티그민메틸황산염 주사제의 사용과 공급을 확대하는 새로운 상업적 기회를 열어줄 수 있습니다.
지식과 진단 부족은 예측 기간 동안 전 세계 네오스티그민메틸황산염 주사제 시장의 성장을 방해할 것으로 예상됩니다.
본 조사의 주요 특징
- 본 보고서에서는 세계의 네오스티그민메틸황산염 주사제 시장을 상세하게 분석하여 2024년을 기준 연도으로 한 예측기간 2025-2032년 시장 규모 및 연평균 성장률(CAGR%)을 제공합니다.
- 또, 다양한 부문에 걸친 잠재적인 수익 성장 기회를 밝혀, 이 시장의 매력적인 투자 제안의 매트릭스에 대해서 해설했습니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 세계의 네오스티그민메틸황산염 주사제 시장에 있어서의 주요한 기업 프로파일을, 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 업적, 전략 등의 파라미터에 근거해 제공합니다.
- 본 보고서로부터 얻을 수 있는 통찰에 의해 마케팅 담당자나 각 기업의 경영진은 장래의 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 관해서, 충분한 정보에 근거한 의사 결정을 실시할 수 있습니다.
- 세계의 네오스티그민메틸황산염 주사제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 판매자, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 하고 있습니다.
- 이해관계자는 세계의 네오스티그민메틸황산염 주사제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- 일관된 기회 지도(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 중증 근육 무력증 및 수술 후 장 마비와 같은 질환의 발생률 증가로 인해 네오스티그민 수요 증가
- 지식과 진단의 부족
- 수의학의 성장
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 출시 및 승인
- PEST 분석
- PORTER 분석
- 합병과 인수 시나리오
제4장 세계의 네오스티그민메틸황산염 주사제 시장 : 코로나 바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급 측면 및 수요 측면 분석
- 경제에 미치는 영향
제5장 세계의 네오스티그민메틸황산염 주사제 시장 : 용량별(2020-2032년)
제6장 세계의 네오스티그민메틸황산염 주사제 시장 : 적응증별(2020-2032년)
제7장 세계의 네오스티그민메틸황산염 주사제 시장 : 유통 경로별(2020-2032년)
제8장 세계의 네오스티그민메틸황산염 주사제 시장 : 최종 용도별(2020-2032년)
제9장 세계의 네오스티그민메틸황산염 주사제 시장 : 지역별(2020-2032년)
- 북미
- 유럽
- 영국
- 독일
- 이탈리아
- 프랑스
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- ASEAN
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC
- 이스라엘
- 기타 중동
- 북아프리카
- 중앙 아프리카
- 남아프리카
제10장 경쟁 구도
- Baxter International Inc.
- Pfizer Inc.
- Fresenius Kabi AG
- Boehringer Ingelheim GmbH
- Mylan NV
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd.
- Sandoz(a division of Novartis)
- Accord Healthcare Inc.
- Lannett Company, Inc.
- Mallinckrodt Pharmaceuticals
- Lupin Limited
제11장 섹션
HBR
영문 목차
Neostigmine Methylsulfate Injection Market is estimated to be valued at USD 171.5 Mn in 2025 and is expected to reach USD 233.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.5% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 171.5 Mn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
4.50% |
2032 Value Projection: |
USD 233.4 Mn |
Neostigmine methylsulfate injection is a cholinesterase inhibitor that is used as an adjunct in the treatment of myasthenia gravis and as an antidote in the treatment of non-depolarizing neuromuscular blocking agent toxicity in the operating room or intensive care unit setting. It acts by inhibiting the acetylcholinesterase enzyme, which normally breaks down the neurotransmitter acetylcholine at the neuromuscular junction. By inhibiting this enzyme, neostigmine methylsulfate prolongs the actions of acetylcholine, increasing neuromuscular transmission and muscle strength. It helps in the management of myasthenia gravis symptoms such as weakness of the skeletal muscles of the extremities, trunk, throat, and eyes. In overdose or sensitive patients, it can cause increased stimulation at the neuromuscular junction and produce side effects such as nausea, increased saliva, and muscle cramps.
Market Dynamics:
The increasing geriatric population will continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The elderly are more susceptible to neurological conditions like myasthenia gravis, which frequently needs to be treated with injections of neostigmine methylsulfate. Rising medical expenditures will also continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The growth of veterinary medicine will create new opportunities for the global neostigmine methylsulfate injection market over the forecast period. Injections of neostigmine methylsulfate are also employed in veterinary medicine, particularly for the treatment of a few neuromuscular diseases in animals. It may open up new commercial prospects to increase the use and availability of neostigmine methylsulfate injections in the veterinary industry.
Lack of knowledge and diagnosis is expected to hamper the growth of the global neostigmine methylsulfate injection market over the forecast period.
Key Features of the Study:
- This report provides an in-depth analysis of the global neostigmine methylsulfate injection market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neostigmine methylsulfate injection market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as a part of this study include Baxter International Inc., Pfizer Inc., Fresenius Kabi AG, Boehringer Ingelheim GmbH, Mylan N.V., Novartis International AG, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Sandoz (a division of Novartis), Accord Healthcare Inc., Lannett Company, Inc., Mallinckrodt Pharmaceuticals, and Lupin Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global neostigmine methylsulfate injection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neostigmine methylsulfate injection market
Detailed Segmentation:
- Global Neostigmine Methylsulfate Injection Market, By Dosage:
- Global Neostigmine Methylsulfate Injection Market, By Indications:
- Myasthenia Gravis
- Reversal of Neuromuscular Blockade
- Global Neostigmine Methylsulfate Injection Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Neostigmine Methylsulfate Injection Market, By End User:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Global Neostigmine Methylsulfate Injection Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profile:
- Baxter International Inc.
- Pfizer Inc.
- Fresenius Kabi AG
- Boehringer Ingelheim GmbH
- Mylan N.V.
- Novartis International AG
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd.
- Sandoz (a division of Novartis)
- Accord Healthcare Inc.
- Lannett Company, Inc.
- Mallinckrodt Pharmaceuticals
- Lupin Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Neostigmine Methylsulfate Injection Market, By Dosage
- Neostigmine Methylsulfate Injection Market, By Indication
- Neostigmine Methylsulfate Injection Market, By Distribution Channel
- Neostigmine Methylsulfate Injection Market, By End User
- Neostigmine Methylsulfate Injection Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rising prevalence of diseases like myasthenia gravis and postoperative ileus requiring neostigmine
- Lack of knowledge and diagnosis
- Growth of veterinary medicine
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Neostigmine Methylsulfate Injection Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Neostigmine Methylsulfate Injection Market, By Dosage, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- 1 mg/mL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- 0.5 mg/mL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
6. Global Neostigmine Methylsulfate Injection Market, By Indication, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Myasthenia Gravis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Reversal of Neuromuscular Blockade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
7. Global Neostigmine Methylsulfate Injection Market, By Distribution Channel, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
8. Global Neostigmine Methylsulfate Injection Market, By End User, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
9. Global Neostigmine Methylsulfate Injection Market, By Region, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region 2021 - 2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sandoz (a division of Novartis)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Accord Healthcare Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lannett Company, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mallinckrodt Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
관련자료
